Compare ALEMBIC PHARMA with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DISHMAN PHARMA ALEMBIC PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 17.5 25.1 69.8% View Chart
P/BV x 7.0 3.3 207.9% View Chart
Dividend Yield % 0.5 0.7 82.5%  

Financials

 ALEMBIC PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs664374 177.4%   
Low Rs412129 319.9%   
Sales per share (Unadj.) Rs208.7197.8 105.5%  
Earnings per share (Unadj.) Rs31.021.2 146.2%  
Cash flow per share (Unadj.) Rs37.134.7 106.9%  
Dividends per share (Unadj.) Rs5.502.00 275.0%  
Dividend yield (eoy) %1.00.8 128.6%  
Book value per share (Unadj.) Rs144.2179.9 80.2%  
Shares outstanding (eoy) m188.5280.69 233.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.3 202.7%   
Avg P/E ratio x17.411.9 146.3%  
P/CF ratio (eoy) x14.57.2 200.1%  
Price / Book Value ratio x3.71.4 266.8%  
Dividend payout %17.79.4 188.1%   
Avg Mkt Cap Rs m101,46120,306 499.7%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m7,4675,355 139.4%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m39,34715,961 246.5%  
Other income Rs m94265 35.3%   
Total revenues Rs m39,44116,226 243.1%   
Gross profit Rs m8,7364,103 212.9%  
Depreciation Rs m1,1521,091 105.7%   
Interest Rs m184944 19.5%   
Profit before tax Rs m7,4932,334 321.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-931 -8,436.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568624 251.4%   
Profit after tax Rs m5,8441,711 341.5%  
Gross profit margin %22.225.7 86.4%  
Effective tax rate %20.926.7 78.3%   
Net profit margin %14.910.7 138.5%  
BALANCE SHEET DATA
Current assets Rs m19,57711,018 177.7%   
Current liabilities Rs m14,8969,517 156.5%   
Net working cap to sales %11.99.4 126.5%  
Current ratio x1.31.2 113.5%  
Inventory Days Days90110 81.2%  
Debtors Days Days4535 130.2%  
Net fixed assets Rs m27,09716,304 166.2%   
Share capital Rs m377161 233.6%   
"Free" reserves Rs m26,81112,907 207.7%   
Net worth Rs m27,18814,516 187.3%   
Long term debt Rs m4,9934,189 119.2%   
Total assets Rs m47,77829,805 160.3%  
Interest coverage x41.73.5 1,201.4%   
Debt to equity ratio x0.20.3 63.6%  
Sales to assets ratio x0.80.5 153.8%   
Return on assets %12.68.9 141.6%  
Return on equity %21.511.8 182.3%  
Return on capital %23.617.5 134.6%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m19,4534,952 392.9%   
Fx outflow Rs m6,065697 870.4%   
Net fx Rs m13,3884,255 314.7%   
CASH FLOW
From Operations Rs m8,1202,786 291.4%  
From Investments Rs m-7,556-1,529 494.2%  
From Financial Activity Rs m590-941 -62.7%  
Net Cashflow Rs m1,153316 364.5%  

Share Holding

Indian Promoters % 74.1 61.4 120.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 3.7 78.4%  
FIIs % 9.1 12.7 71.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 22.1 62.9%  
Shareholders   49,328 46,261 106.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NATCO PHARMA  FRESENIUS KABI ONCO.  FDC  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Lower Oxygen Supplies to Affect 5 Sectors, Tata Steel's Blockchain Transaction, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a positive note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 375 points (up 0.8%).

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Apr 22, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS